An interim cancer‑trial analysis found 71.2% three‑year survival versus 45.8% in a historical group.

Rákkutatás · Prostate cancer

The interim 3‑year overall survival rate among OST‑HER2 treated patients was 71.2 %, compared with 45.8 % of patients in the comparable combined historical control group (p = 0.002, 41 total enrolled patients, with visits for the two remaining patients who have not reached 3‑years from enrollment scheduled for September 2026 and early October 2026, respectively, and 6 patients lost to follow‑up).

OS Therapies reported an interim 3‑year overall survival rate of 71.2 % for OST‑HER2‑treated patients in its Phase 2b pulmonary metastatic osteosarcoma trial, versus 45.8 % in a comparable combined historical control group (p = 0.002).

The 71.2 % survival rate represents a statistically significant improvement over historical controls, supporting regulatory engagement for accelerated approval and early market access.

Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.

Eredeti forrás

Kapcsolódó jelek